MedPath

Reduceren van de4 kosten van de controle van patienten met niet-spier-invasief blaaskanker

Suspended
Conditions
Bladder Cancerbladder cancer, non-muscle invasive, surveillance, cystoscopy, urine testBlaaskanker, oppervlakkig blaaskanker, controles, cystoscopie, urine test
Registration Number
NL-OMON28752
Lead Sponsor
Erasmus MC
Brief Summary

A

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
Not specified
Target Recruitment
450
Inclusion Criteria

patients under surveillance for recurrences after a NMIBC primary tumor

Exclusion Criteria

under 21 years of age

patients upgraded at reTUR to NMIBC

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
15% extra recurrences detected in maximal care arm; <br>40% percentage decrease in cystoscopies in optimal care arm; <br>costs of optimal care vs classic care: 4000 euro less; <br>
Secondary Outcome Measures
NameTimeMethod
lower stage recurrences in high-risk group
© Copyright 2025. All Rights Reserved by MedPath